Park Avenue Securities LLC increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 28.2% during the ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) today and set a price target of ...

Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...

Gateway Investment Advisers LLC raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 47.5% during the ...

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through ...

The renowned manufacturer and global supplier of clinical diagnostics and life science research products has a market capitalization of $9.57 billion. Bio-Rad’s earnings surpassed estimates in each of ...

New Vericheck ddPCR Empty-Full Capsid Kits for AAV Serotypes 2 and 8 Provide Precise Measurement of Viral Titer and Capsid ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for ...

Here is how Adaptive Biotechnologies (ADPT) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.

Gastric cancer diagnostics companies are Abbott, BD, Bio-Rad Laboratories, Roche, Siemens Healthineers, Thermo Fisher Scientific, Pillar Biosciences, ETC ...